| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 8.060 | 15.142 | 11.115 | 12.773 | 12.279 | 7.393 | 12.767 | 12.813 | 11.881 | 7.141 |
| Total Income - EUR | 8.060 | 15.142 | 11.124 | 12.773 | 12.279 | 7.393 | 12.767 | 39.957 | 11.881 | 7.141 |
| Total Expenses - EUR | 6.885 | 7.228 | 18.176 | 17.870 | 17.637 | 16.655 | 16.751 | 7.589 | 5.784 | 3.927 |
| Gross Profit/Loss - EUR | 1.174 | 7.914 | -7.052 | -5.097 | -5.358 | -9.262 | -3.984 | 32.368 | 6.096 | 3.214 |
| Net Profit/Loss - EUR | 924 | 7.460 | -7.390 | -5.483 | -5.728 | -9.486 | -4.369 | 31.165 | 5.121 | 2.751 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Angiobat Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.638 | 1.399 | 50.574 | 38.275 | 24.820 | 13.239 | 2.031 | 207 | 0 | 845 |
| Current Assets | 11.696 | 20.645 | 8.107 | 13.812 | 20.979 | 22.129 | 8.611 | 14.235 | 20.616 | 19.946 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 2.318 | 15.494 | 275 | 0 | 621 | 0 | 20 | 0 | 0 | 0 |
| Cash | 9.378 | 5.151 | 7.832 | 13.812 | 20.358 | 22.129 | 8.591 | 14.235 | 20.616 | 19.946 |
| Shareholders Funds | 11.855 | 19.194 | 11.479 | 5.785 | -55 | -9.540 | -13.697 | 17.425 | 22.493 | 25.119 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 3.315 | 3.632 | 47.597 | 46.705 | 45.861 | 44.992 | 24.339 | 943 | 354 | 167 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Angiobat Srl